Rpharmy Memorial
Approved Hospital Formulary
Formulary Addition Requisition (Position 1)
Rpharmy Memorial Formweb Change Request (Position 2)
Search by name
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Black Box Warning
LASA
Do Not Crush
Therapeutic Interchange
Non-Formulary
REMS
High Cost Drugs
Renal Dosing
Hazardous Drugs
Restricted
Questions & Suggestions (Position 3)
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
News
Boards
Rpharmy Memorial
Approved Hospital Formulary
Formulary Addition Requisition (Position 1)
Rpharmy Memorial Formweb Change Request (Position 2)
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Black Box Warning
LASA
Do Not Crush
Therapeutic Interchange
Non-Formulary
REMS
High Cost Drugs
Renal Dosing
Hazardous Drugs
Restricted
Questions & Suggestions (Position 3)
Webpage Links
Hazardous Drugs
Please review each of these drugs carefully.
baricitinib
Group 1 (NIOSH 2016)
Table 1 (NIOSH 2020)
bortezomib
Rhazdrugs
cabazitaxel
Group 1 (NIOSH 2016)
Table 1 (NIOSH 2020)
carBAMazepine
Group 2 (NIOSH 2016)
Table 2 (NIOSH 2020)
clonazePAM
Group 3 (NIOSH 2016)
Table 2 (NIOSH 2020)
colchicine
Group 3 (NIOSH 2016)
Table 2 (NIOSH 2020)
finasteride
Group 3 (NIOSH 2016)
Table 2 (NIOSH 2020)
fluconazole
Group 3 (NIOSH 2016)
Table 2 (NIOSH 2020)
hydroxyurea
Group 1 (NIOSH 2016)
Table 1 (NIOSH 2020)
levonorgestrel
Group 2 (NIOSH 2016) - progestins
Table 2 (NIOSH 2020) - progestins
megestrol
Group 1 (NIOSH 2016)
Table 2 (NIOSH 2020)
methotrexate
Rhazdrugs
miSOPROStol
Group 3 (NIOSH 2016)
Table 2 (NIOSH 2020)
oxytocin
Group 3 (NIOSH 2016)
Table 2 (NIOSH 2020)
PARoxetine
Group 3 (NIOSH 2016)
Table 2 (NIOSH 2020)
risperiDONE
NIOSH has determined it is unlikely that risperidone (Risperidal®) poses a carcinogenic, reproductive, or developmental hazard to workers in a healthcare setting and is no longer considered a hazardous drug by NIOSH. (1/10/2019)
spironolactone
Group 2 (NIOSH 2016)
Table 2 (NIOSH 2020)
temazepam
Group 3 (NIOSH 2016)
Table 2 (NIOSH 2020)
topiramate
Group 3 (NIOSH 2016)
Table 2 (NIOSH 2020)
valGANciclovir
Group 2 (NIOSH 2016)
Table 1 (NIOSH 2020)
warfarin
Group 3 (NIOSH 2016)
Table 2 (NIOSH 2020)
ziprasidone
Group 3 (NIOSH 2016)
Table 2 (NIOSH 2020)
Add Formweb to your mobile device